10. SEGMENTS

12 Months Ended

Mar. 31, 2019

Segment Reporting [Abstract]

SEGMENTS

10. SEGMENTS

We operate our businesses principally through two reportable segments: Aethlon, which represents our therapeutic business activities, and ESI, which represents our diagnostic business activities. Our reportable segments have been determined based on the nature of the potential products being developed. We record discrete financial information for ESI and our chief operating decision maker reviews ESI’s operating results in order to make decisions about resources to be allocated to the ESI segment and to assess its performance.

Aethlon’s revenue is generated primarily from government contracts to date and ESI does not yet have any revenues. We have not included any allocation of corporate overhead to the ESI segment.

The following tables set forth certain information regarding our segments:

	Fiscal Years Ended March 31,
	2019			2018
Revenues:
Aethlon	$	229,625		$	149,625
ESI		–			–
Total Revenues	$	229,625		$	149,625
Operating Losses:
Aethlon	$	(5,875,094	)	$	(4,729,719	)
ESI		(123,923	)		(101,397	)
Total Operating Loss	$	(5,999,017	)	$	(4,831,116	)
Net Losses:
Aethlon	$	(6,095,581	)	$	(5,598,440	)
ESI		(123,923	)		(101,397	)
Net Loss Before Non-Controlling Interests	$	(6,219,504	)	$	(5,699,837	)
Cash:
Aethlon	$	3,827,555		$	6,972,450
ESI		519			1,620
Total Cash	$	3,828,074		$	6,974,070
Total Assets:
Aethlon	$	4,122,445		$	7,350,284
ESI		519			1,620
Total Assets	$	4,122,964		$	7,351,904
Capital Expenditures:
Aethlon	$	–		$	24,823
ESI		–			–
Capital Expenditures	$	–		$	24,823
Depreciation and Amortization:
Aethlon	$	30,695		$	35,658
ESI		–			–
Total Depreciation and Amortization	$	30,695		$	35,658
Interest Expense:
Aethlon	$	220,487		$	361,597
ESI		–			–
Total Interest Expense	$	220,487		$	361,597